- Price
- $3.63
- Day
- -2.42%
- Mkt Cap
- $330.28M
- 52W Range
- $1.85 – $5.15
- Volume
- 170.9K
- Beta
- 0.54
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:
Read full article
AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ: SABS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 375,000 shares of the company's stock, valued at approximately $1,462,000. AWM Investment Company Inc. owned 0.41% of SAB
Read full article